metricas
covid
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology P-38 EVALUATION OF THE GENETIC AND VIROLOGICAL PROFILE OF PREGNANT WOMEN INFECTE...
Información de la revista
Vol. 29. Núm. S3.
Abstracts of the 2023 Annual Meeting of the ALEH
(diciembre 2024)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Vol. 29. Núm. S3.
Abstracts of the 2023 Annual Meeting of the ALEH
(diciembre 2024)
Acceso a texto completo
P-38 EVALUATION OF THE GENETIC AND VIROLOGICAL PROFILE OF PREGNANT WOMEN INFECTED WITH HEPATITIS B AND C VIRUSES IN A REFERENCE CENTER IN RIO DE JANEIRO, BETWEEN 2016 AND 2022
Visitas
12
Kaio Ferreira Callebe Pedro1, Vinicius Mello Motta1, Giovana Nascimento Guimarães Santos1, Giovana Angelice Paula1, Paulo Sergio Sousa Fonseca1, Aryele Raíra Pereira da Silva1, Nathalia Balassiano1, Caroline Baldin1, Poliana Fernandes1, Girleide Oliveira Pereira2, Livia Villar Melo1, Barbara Lago Vieira3, Lia Laura Lewis-Ximenez1
1 Laboratório de Hepatites Virais, Fundação Oswaldo Cruz, Rio de Janeiro, Brasil
2 Secretaria de Saúde do Rio de Janeiro, Rio de Janeiro, Brasil
3 Laboratório de Hepatites Virais, Fundação Oswaldo Cruz; Instituto de Tecnologia em Imunobiológicos - Bio Manguinhos, Rio de Janeiro, Brasil
Este artículo ha recibido
Información del artículo
Suplemento especial
Este artículo forma parte de:
Vol. 29. Núm S3

Abstracts of the 2023 Annual Meeting of the ALEH

Más datos
Conflict of interest

No

Introduction and Objectives

It is estimated that there are around 400 million people living with hepatitis B (HBV) and/or C virus (HCV) infections worldwide. This situation is relevant because both viruses can be transmitted vertically (VT). Despite efforts to prevent VT, many measures still need to be reinforced, especially regarding the spread of clinically relevant viral variants. Therefore, this study aimed to demonstrate the clinical/laboratory profile of pregnant women identified as positive for HBV and HCV during prenatal care, and referred to a specialized viral hepatitis unit in Rio de Janeiro between 2016-2022, and to identify those with clinically relevant mutations that can be transmitted vertically.

Patients / Materials and Methods

To this end, all pregnant women with positive rapid tests were retested by eletrochemioluminescence using commercial tests for HBV antigens and antibodies against HBV and HCV. In addition, molecular tests were carried out to quantify HBV DNA and/or HCV RNA. Liver enzyme tests were also carried out in order to classify pregnant women according to HBV clinical phase.

Results and Discussion

Two hundred and thirty-two pregnants women with HBV and HCV infection were analyzed. Among the 138 pregnant women with HBV, 95% had HBeAg-negative chronic infection and the mean viral load was 3.70 log IU/ml. Up to now, 6 samples were sequenced, Genotypes A1 (n=5/6,83%) and D3 (n=1/6,16%) were identified and the mutation Y100C was found. In 94 pregnant women with HCV, 75.7% had HCV RNA successfully amplified, with subtypes 1a (n=12/33; 36,4%), 1b (n=17/33; 51,5%) and 3a (n=3/33; 9,1%) detected. Clinically relevant mutations were found V321L, V321IV, C316N.

Conclusions

Identifying mutations in HBV and HCV infections is crucial for epidemiological surveillance and postpartum treatment. Our findings highlight the importance of monitoring drug-resistant mutations in pregnant women with these infections.

El Texto completo está disponible en PDF
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos